Literature DB >> 16061827

Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition.

Gerasimos E Krassas1, Nikolaos Pontikides, Kostas Loustis, Georgios Koliakos, Theodoros Constantinidis, Dimitrios Panidis.   

Abstract

BACKGROUND: Resistin is a recently discovered peptide hormone that belongs to a family of tissue-specific resistin-like molecules. To date, very few studies have reported on resistin concentrations in hyperthyroid patients, and they present controversial results.
OBJECTIVES: To undertake a controlled, prospective study to investigate resistin concentrations in hyperthyroidism before and after restoration of euthyroidism and to correlate the results with body weight, body fat, waist circumference and body mass index (BMI). PATIENTS AND METHODS: A total of 43 hyperthyroid patients (12 men and 31 women) were investigated, in addition to 23 controls. Anthropometric parameters and resistin concentrations were measured. All the patients commenced taking antithyroid drugs and 3-4 months later the same investigations were performed in 36 of the 43 individuals.
RESULTS: Hyperthyroid patients exhibited increased resistin concentrations in comparison with controls. Normalization of thyroid hormones was accompanied by a significant decrease in resistin concentration. A sex difference was also found, men showing a significant decrease in resistin concentrations, whereas in women no such difference was found. Resistin concentrations did not correlate with different anthropometric parameters, age and thyroid hormones, either before or after treatment.
CONCLUSIONS: This study demonstrates for the first time that, although resistin concentrations are increased in hyperthyroidism, they are not associated with body weight, body fat, waist circumference or BMI, which makes it unlikely that resistin plays a crucial part in thermogenesis and energy homeostasis in thyrotoxic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061827     DOI: 10.1530/eje.1.01963

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters.

Authors:  G E Krassas; N Pontikides; K Loustis; G Koliakos; T Constantinidis; T Kaltsas
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

2.  Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.

Authors:  L Sieminska; D Niedziolka; A Pillich; B Kos-Kudla; B Marek; M Nowak; H Borgiel-Marek
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

3.  Experimental hyperthyroidism decreases gene expression and serum levels of adipokines in obesity.

Authors:  Renata de Azevedo Melo Luvizotto; André Ferreira do Nascimento; Maria Teresa de Síbio; Regiane Marques Castro Olímpio; Sandro José Conde; Ana Paula Lima-Leopoldo; André Soares Leopoldo; Antonio Carlos Cicogna; Célia Regina Nogueira
Journal:  ScientificWorldJournal       Date:  2012-05-03

4.  Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave's disease.

Authors:  Ying Peng; Yicheng Qi; Fengjiao Huang; Xinxin Chen; Yulin Zhou; Lei Ye; Weiqing Wang; Guang Ning; Shu Wang
Journal:  Oncotarget       Date:  2016-11-29

5.  Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy.

Authors:  Duygu Yazgan Aksoy; Nese Cinar; Ayla Harmanci; Jale Karakaya; Bulent Okan Yildiz; Aydan Usman; Miyase Bayraktar
Journal:  Med Sci Monit       Date:  2013-03-22

6.  Serum resistin and insulin-like growth factor-1 levels in patients with hypothyroidism and hyperthyroidism.

Authors:  Ceren Eke Koyuncu; Sembol Turkmen Yildirmak; Mustafa Temizel; Tevfik Ozpacaci; Pinar Gunel; Mustafa Cakmak; Yüksel Gülen Ozbanazi
Journal:  J Thyroid Res       Date:  2013-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.